Mizuho Issues Pessimistic Forecast for Axsome Therapeutics (NASDAQ:AXSM) Stock Price

Mizuho lowered its price target for Axsome Therapeutics (NASDAQ:AXSM) from $310 to $306, while maintaining an "outperform" rating, indicating a potential 40% upside. This comes after the company reported a quarterly loss of $1.26 per share, missing expectations, despite a 57.4% year-over-year revenue increase to $191.2 million. Insider selling, including a significant sale by CEO Herriot Tabuteau, also occurred, though institutional investors still hold a substantial 81.49% of shares.